1. Angiotensin-converting enzyme inhibitors can attenuate reflex sympathetic vasoconstriction in vivo. We have investigated the effects of captopril (SQ 14 225) on adrenergic vasoconstrictor mechanisms in isolated, KrebsRinger solution perfused, rat mesenteric arteries.
Introduction
Inhibitors of angiotensin-converting enzyme such as captopril (SQ 14 225), have an antihypertensive effect in man and in rats with renal and spontaneous hypertension [ 1, 21. This effect is thought to be a consequence of a reduction in the levels of the pressor hormone angiotensin I1 and of increased levels of vasodilator kinins. It has been demonstrated that converting enzyme inhibitors attenuate reflex 'sympathetic vasoconstriction [31. This could be due to either a central or a peripheral effect of the inhibitor. As captopril also decreases the pressor response evoked by electrical stimulation of the spinal efferent nerves in the pithed rat [41, the drug must interfere with peripheral adrenergic neuro-effector mechanisms.
Angiotensin I1 is known to potentiate vasoconstrictor responses evoked by exogenous and endogenous noradrenaline [5, 61. In addition, bradykinin can modulate sympathetic vasoconstriction [7, 81. Therefore, captopril could indirectly depress sympathetic vasoconstriction by altering the levels of these peptides. Alternatively, the drug could have a direct effect at the adrenergic neuro-effector junction, independent
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of peptide hormones. We have investigated these possibilities with an isolated perfused mesenteric artery preparation.
Materials and methods

Methods
Male Wistar rats (220-300 g, Alderley Park strain) were anaesthetized with 60 mg of pentobarbitone sodium/kg intraperitoneally (i.p.). The abdomen was opened and the superior mesenteric artery cannulated [9, 101. The mesenteric artery and arterioles were removed and placed in a bath of Krebs-Ringer solution (37OC). The mesenteric artery preparation was perfused at a flow rate of 6.5 ml/min with a roller pump (Gilson, Minipuls 2). The composition of the Krebs-Ringer perfusate (mmol/l) was NaCl 118.2, KCI 4.7, MgSO, 1.2, KH,PO, 1.2, CaCI, 2.5, NaHCO, 25, calcium disodium ethylenediaminetetra-acetic acid 0.026 and glucose 5.5, aerated with CO, + 0, (1: 19, v/v) and maintained at 37OC. The pH of the perfusate was 7.35; this was not altered by the highest concentration of captopril (3 x lo-, mol/l) used in the experiments. Mesenteric artery preparations were allowed to equilibrate for 1 h before commencing the experiment. The basal perfusion pressure of the preparation stabilized in 5-10 min and remained stable for at least 6 h.
Agonist drugs (noradrenaline and KCI) were injected in volumes of 0.02 ml, at 2-5 min intervals, through a rubber tube proximal to the cannula. When KCl was used, the tissue was perfused with Krebs-Ringer solution containing 5 x mol of phentolamine/l to block the effects of catecholamines released by depolarization of the sympathetic nerves [ 111. When the tissue was exposed to angiotensin I or 11, bradykinin, saralasin or captopril, they were added to the Krebs-Ringer solution and perfused continuously. The nerves supplying the mesenteric arteries were electrically stimulated (2 ms pulse width, supramaximal voltage 28-32 V, 20 s trains) via peri-arterial platinum electrodes. Electrical stimulation by this method has been shown previously to activate postganglionic adrenergic sympathetic nerves in) this preparation [91. Vasoconstrictor responses were recorded as increases in perfusion pressure, with a pressure transducer and chart recorder.
Stability of the preparation
Responses evoked by submaximal frequencies of electrical stimulation could be repeated without any significant deterioration in their amplitude. It has been shown previously that dose-response curves to noradrenaline are stable and repeatable in this preparation [ 101. In all experiments, in which dose-response curves to angiotensin were repeated, the tissues were initially exposed to a high concentration of angiotensin I or I1 (7.8-9.7 x lo-' mol/l) to stabilize their sensitivity to the peptide.
Experimental protocol
Effect Effect of captopril or saralasin on the angiotensin-induced potentiation of responses to nerve stimulation. Tissues were exposed to angiotensin I or I1 as described previously. They were then perfused with Krebs-Ringer solution containing captopril or saralasin. An initial 30 min equilibration period was allowed, during which time electrical stimulation (at 5 min intervals) was continued. The tissues were then perfused with increasing concentmations of angiotensin I or I1 in the presencdf the antagonist. Finally the tissues were perfused with normal Krebs-Ringer solution until stable control responses were achieved.
Drugs used
These were as follows: [Ileu5]angiotensin I (Calbiochem); [Valslangiotensin I1 (Hypertensin, Ciba); Bar', Alas]angiotensin I1 (Saralasin, Beckman); bradykinin tri-acetate (Sigma); captopril (SQ 14 225, Squibb); Lnoradrenaline bitartrate (Sigma); phentolamine mesylate (Ciba).
Analysis of results
When the effects of peptide hormones on responses evoked by electrical stimulation or noradrenaline were examined, the control responses in normal Krebs-Ringer solution, before and after exposure to the hormone, were meaned. Responses evoked in the presence of the hormone were expressed as a percentage change from the mean control value. The results are expressed as means ~S E M .
Significant differences ( P < 0.05) were evaluated by a paired Student's t-test and by one-way analysis of variance.
Results
Effect of captopril on vasoconstrictor responses evoked by nerve stimulation, by noradrenaline and by potassium chloride
In eight tissues captopril (low5 mol/l) had no significant effect on the amplitude of vasoconstrictor responses evoked by 4, 8 and 16 Hz electrical stimulation (Fig. l) , but caused a small significant decrease ( P < 0.05) in the amplitude of the response evoked by 12 Hz. A higher concentration of captopril ( mol/l, n = 8) caused significant decreases in the amplitude of responses evoked by electrical stimulation at 12 and 16 Hz ( P < 0.05, Fig. 1 ). This effect was more pronounced at 3 x mol of captopril/l and was highly significant at 12 and 16 Hz ( P < 0.01, Fig. 1 ).
Captopril at mol/l had no significant effect on responses evoked by exogenous noradrenaline (n = 7, Fig. 2 ). Higher concentrations
(1 x 3 x mol/l) significantly attenuated the vasoconstrictor responses evoked by submaximal doses of noradrenaline ( P < 0.05, n = 6 and P < 0.01, n = 6 respectively, Fig. 2 ).
Vasoconstrictor responses, evoked by potassium chloride, were not significantly affected by 3 x Effect of angiotensin and bradykinin on vasoconstrictor responses evoked by nerve stimulation and by noradrenaline Both angiotensin I and I1 caused significant dose-related increases in the amplitude of vasoconstrictor responses evoked by nerve stimulation (Figs. 4, 5) . Responses evoked by exogenous noradrenaline were also potentiated by angiotensin 11. This effect was significantly smaller than the potentiation of responses evoked by electrical stimulation in the same tissues (Table 1 ). The concentrations of angiotensin I and I1 used in these experiments had no significant sustained effect on the basal perfusion pressure of the mesenteric vessels. In six tissues bradykinin (8-9 x lo-'' mol/l) had no significant effect on the amplitude of vasoconstrictor responses evoked by electrical stimulation (change in response amplitude -2 f 2.6%). mol of captopril/l (Fig. 3, n = 6 ). Saralasin (lo-* mol/l) had no effect on the amplitude of responses evoked by electrical stimulation in the absence of exogenous angiotensin (control = 9 -0 0.6 mmHg, saralasin 
=9.2 f 0-7 mmHg, n = 12). The potentiating effects of both angiotensin I (2.3 x 10-9-7.8 x mol/l) and angiotensin I1 (2.9 x 9.7 x lo-* mol/l) were reduced by saralasin (P < 0.05, II = 6) and this resulted in a shift of the angiotensin dose-response curves to the right of control (Fig. 4) . The magnitude of this dose-response curve shift was similar for both peptides. Captopril (6.7 x 2 x lop6 mol/l) had no significant effect on the amplitude of responses evoked by electrical stimulation in the absence of exogenous angiotensin (control = 9.7 k 0.5 and 8-8 f-1 . 1 mmHg respectively; in the presence of captopril = 9.4 k 0.6 and 8.4 f 1.1 mmHg respectively). Both concen- trations of converting enzyme inhibitor significantly reduced the adrenergic-potentiating effect of angiotensin I ( Table 2 , Fig. 5 ). However, the potentiation caused by angiotensin I1 was not affected by captopril (2 x mol/l, Fig. 5 ).
Discussion
The results of the present study indicate that captopril has two potential inhibitory effects at the vascular adrenergic neuro-effector junction. The inhibitory effect of low concentrations of the drug depends on the presence of angiotensin I, in quantities sufficient to potentiate sympathetic vasoconstriction. By contrast, the inhibitory effect of high concentrations of the converting enzyme inhibitor occurs in the absence of exogenous peptide hormones. Isolated mesenteric vessels, perfused with Krebs-Ringer solution, cannot contain significant amounts of endogenous angiotensin I or 11, as saralasin alone had no effect on the responses evoked by electrical stimulation. Therefore the inhibitory effects of high concentrations of captopril cannot be due to an interaction with endogenous angiotensin. Likewise it cannot be due to elevated levels of endogenous kinins, since bradykinin did not affect the amplitude of responses evoked by nerve stimulation. Since captopril at high concentrations attenuated vasoconstrictor responses evoked by sympathetic nerve stimulation and by exogenous noradrenaline, this inhibitory effect must occur at the vascular smooth muscle cell. Responses evoked by the non-adrenergic stimulant, KCl, were unaffected by captopril. This indicates that the postjunctional inhibitory effect of captopril has some specificity. However, an investigation of the drug's inhibitory effect on responses evoked by additional vasoconstrictor receptor agonists is required fully to elucidate its nature.
The observation that captopril antagonizes responses to noradrenaline, contrasts with the work of Rubin et al. [12] who were unable to demonstrate an effect of captopril (5 x mol/l) on noradrenaline-evoked contractions of large arteries and veins. Differences in the sensitivity of mesenteric vessels and of large arteries and veins probably account for this discrepancy. It is known that certain cc-adrenoceptor antagonists are more potent on mesenteric resistance vessels than on large arteries [lo].
The relevance of the postjunctional inhibitory effect of high concentrations of captopril to its therapeutic action in man is unknown. Considering the doses administered, up to 1 g [ll, and the relative potency of oral and intravenous doses [121, peak plasma concentrations of 1-2 mg/l (5 x 10-6-1 x 10-5 mol/l) are probable. It is therefore unlikely that plasma concentrations of the drug in man could achieve the levels required mol/l) to exert this blocking effect. However, this effect could become significant in animal studies if excessive doses of captopril are given.
Converting enzyme inhibitors alter the plasma levels of angiotensin I1 and bradykinin in man [13]. The role of the elevated kinin levels in the antihypertensive response to captopril is controversial [14, 151. Our studies do not allow any conclusion to be reached concerning the role of kinins in the clinical effect of the drug. However, as a high concentration of bradykinin did not affect the vasoconstrictor response to nerve stimulation in the rat mesenteric artery preparation, it is unlikely that this peptide is involved in the effect of captopril on adrenergic reflexes. By contrast, angiotensin I1 potentiated vasoconstrictor responses evoked by sympathetic nerve stimulation, and to a lesser extent by exogenous noradrenaline. This effect has been reported previously [ 5 , 61 and is clearly not due to a direct constrictor action of the peptide. A number of factors have been proposed to explain this potentiating effect; these include the facilitation of neurotransmitter release, blockade of neuronal uptake and increased sensitivity of the vascular smooth muscle [5, 161. Since responses to endogenously released noradrenaline (nerve stimulation) were potentiated to a greater extent than those to the exogenous catecholamine, one effect of angiotensin I1 in this preparation must be the facilitation of neurotransmitter release.
Angiotensin I and I1 caused similar degrees of potentiation of the responses evoked by electrical stimulation of the sympathetic nerves. As the angiotensin I1 antagonist, saralasin, displaced the dose-response curves for the two peptides to the same extent, it is likely that angiotensin I is converted into angiotensin I1 in the mesenteric vessels before exerting its potentiating effect. Low concentrations of captopril blocked this local vascular conversion and selectively antagonized the effect of angiotensin I. Therefore, in situations where endogenous angiotensin levels , are sufficient to potentiate adrenergic responses, captopril and other converting enzyme inhibitors will reduce sympathetic vasoconstrictor tone by inhibiting the production of angiotensin 11. This could account for the attenuation of reflex and stimulated sympathetic vasoconstriction ob-served in experimental animals t3, 41 and could contribute to the antihypertensive effect of captopril in man.
